GANCICLOVIR/CIDOFOVIR CMV RETINITIS TRIAL

更昔洛韦/西多福韦 CMV 视网膜炎试验

• 批准号: 6291129
• 负责人: JOSEPH WHEAT
• 金额: $ 0.04万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6291129
• 关键词: AIDS; antiviral agents; clinical research; clinical trials; cytomegalovirus retinitis; eye disorder chemotherapy; ganciclovir; human subject; human therapy evaluation

The Ganciclovir and Cidofovir CMV Retinitis Trial (GCCRT) is a study of two treatment regimens that are administered without the use of a central venous catheter for both newly diagnosed and relapsed AIDS-related CMV retinitis. The two regimens are: 1) ganciclovir intraocular device plus oral ganciclovir and 2) intravenous cidofovir. The primary objective of the trial is to compare the newest CMV retinitis drug, cidofovir, to a commonly used treatment regimen, the ganciclovir intraocular device plus oral ganciclovir, with respect to efficacy in preventing vision loss. A secondary objective is to compare a treatment regimen that incorporates highly active local therapy (the ganciclovir device) with a treatment regimen that does not.

更昔洛韦和西多福韦CMV视网膜炎试验（GCCRT）是一项研究两种治疗方案，不使用中心静脉导管管理新诊断和复发的艾滋病相关的CMV视网膜炎。 两种方案是：1）更昔洛韦眼内装置+口服更昔洛韦和2）静脉注射西多福韦。 该试验的主要目的是比较最新的CMV视网膜炎药物西多福韦（cidofovir）与常用的治疗方案更昔洛韦眼内装置加口服更昔洛韦（ganciclovir）在预防视力丧失方面的疗效。 第二个目的是比较一个治疗方案，包括高活性的局部治疗（更昔洛韦装置）与治疗方案，不。